| Safety and Immunogenicity Study of SCB-1019T in Children (NCT06666179) | Clover Biopharmaceuticals AUS Pty | 2025-10-01 |
| Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults (NCT06984094) | Clover Biopharmaceuticals AUS Pty | 2025-06-18 |
| First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults (NCT06194318) | Clover Biopharmaceuticals AUS Pty | 2023-12-13 |
| Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults (NCT06567457) | Clover Biopharmaceuticals AUS Pty | 2023-10-01 |
| Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults (NCT05926440) | Clover Biopharmaceuticals AUS Pty | 2023-08-17 |
| Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age (NCT05193279) | Clover Biopharmaceuticals AUS Pty | 2022-10-05 |
| Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults (NCT05188677) | Clover Biopharmaceuticals AUS Pty | 2022-06-13 |
| Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults (NCT05228314) | Clover Biopharmaceuticals AUS Pty | 2022-05-30 |
| Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration (NCT04919096) | Clover Biopharmaceuticals AUS Pty | 2022-04-01 |
| Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases (NCT05012787) | Clover Biopharmaceuticals AUS Pty | 2021-11-12 |
| Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults (NCT04950751) | Clover Biopharmaceuticals AUS Pty | 2021-08-01 |
| A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19 (NCT04672395) | Clover Biopharmaceuticals AUS Pty | 2021-03-24 |
| Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19. (NCT04932824) | Clover Biopharmaceuticals AUS Pty | 2021-01-19 |
| SCB-2019 as COVID-19 Vaccine (NCT04405908) | Clover Biopharmaceuticals AUS Pty | 2020-06-19 |
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions (NCT03869697) | Clover Biopharmaceuticals AUS Pty | 2019-11-20 |
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies (NCT03443674) | Clover Biopharmaceuticals AUS Pty | 2018-06-18 |